<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04072367</url>
  </required_header>
  <id_info>
    <org_study_id>VS-007</org_study_id>
    <nct_id>NCT04072367</nct_id>
  </id_info>
  <brief_title>FIrst-Pass Reperfusion With the NeVa Stent-Retriever Trial</brief_title>
  <acronym>FIRST</acronym>
  <official_title>A Prospective, Randomized, Open-Label, Multi-Center, Assessor-Blinded Study Designed to Compare the Safety, Performance and Efficacy of the NeVatm Stent Retriever Versus the Solitairetm Stent Retriever</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vesalio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vesalio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the safety, performance and efficacy of blood clot&#xD;
      (thrombus) removal in subjects presenting with acute ischemic stroke with the NeVa versus the&#xD;
      Solitaire stent retrievers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A pivotal, randomized, open label, assessor-blinded, 90-day study designed to compare the&#xD;
      safety, performance and efficacy of thrombus removal in subjects aged ≥ 18 years presenting&#xD;
      with acute ischemic stroke with the NeVa versus the Solitaire stent retrievers.&#xD;
&#xD;
      A total of 414 eligible subjects will be randomized in a 1:1 ratio to one of two treatment&#xD;
      groups:&#xD;
&#xD;
        -  Active Treatment Group&#xD;
&#xD;
        -  Control Device&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study was withdrawn due to a change in company strategy.&#xD;
  </why_stopped>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reperfusion rate</measure>
    <time_frame>post-procedure day 0</time_frame>
    <description>The primary study endpoint is the reperfusion rate of the occluded target vessel (defined by an eTICI score ≥ 2b) following one single pass using the assigned stent retriever device(s)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stent retriever comparison</measure>
    <time_frame>Day 90</time_frame>
    <description>The secondary endpoint is the proportion of subjects treated with the NeVa device with good clinical outcomes at the Day 90 evaluation (defined as mRS score ≤ 2) when compared to the subjects treated with the predicate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Active Treatment Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>NeVa Stent Retrievers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Device</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Solitare Stent Retrievers</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeVa Stent Retrievers</intervention_name>
    <description>thrombus removal</description>
    <arm_group_label>Active Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Solitaire Stent Retrievers</intervention_name>
    <description>thrombus removal</description>
    <arm_group_label>Control Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  A new focal disabling neurologic deficit consistent with acute cerebral ischemia&#xD;
&#xD;
          -  NIHSS score ≥ 6;&#xD;
&#xD;
          -  Prestroke mRS score of ≤ 2;&#xD;
&#xD;
          -  Angiographic confirmation by DSA of an occlusion (eTICI 0-1) of the intracranial ICA,&#xD;
             MCA-M1, MCA-M2, basilar artery, or intracranial vertebral artery with or without&#xD;
             tandem involvement of the cervical ICA or cervical vertebral artery;&#xD;
&#xD;
          -  Imaging Criteria:&#xD;
&#xD;
               1. Strokes in the Anterior Circulation:&#xD;
&#xD;
                    -  Non-Contrast CT (NCCT): ASPECTS 6 to 10 on baseline CT, or&#xD;
&#xD;
                    -  CT perfusion (with Automated Volume Calculation): core infarct volume ≤ 70cc&#xD;
                       and Mismatch Ratio ≥ 1.5&#xD;
&#xD;
                    -  CT perfusion (without Automated Volume Calculation): ASPECTS 6 to 10 on the&#xD;
                       CBV maps with Visualized MTT or TMax - CBV Mismatch greater than 50%, or&#xD;
&#xD;
                    -  Brain MRI: ASPECTS 6 to 10 (and &lt;70cc if Automated Volume Calculation is&#xD;
                       available) on baseline diffusion-weighted sequence (DWI).&#xD;
&#xD;
               2. Strokes in the Posterior Circulation: pc-ASPECTS score 8 to 10 on baseline NCCT,&#xD;
                  CTA-source images, or DWI MRI.&#xD;
&#xD;
                    -  Subjects for whom IV-tPA is indicated and who are available for treatment,&#xD;
                       are treated with IV-tPA within 4.5 hours of stroke onset (onset time is&#xD;
                       defined as the last time when the subject was witnessed to be at baseline),&#xD;
                       with verification that the subject has received/is receiving the correct IV&#xD;
                       t-PA dose for the estimated weight&#xD;
&#xD;
                    -  Arterial puncture within 12 hours of symptom onset (or time last seen well -&#xD;
                       TLSW), thrombectomy procedure able to be completed within 2 hours from&#xD;
                       procedure start (arterial puncture).&#xD;
&#xD;
                    -  Subject or legal representative is able and willing to give informed&#xD;
                       consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Rapid neurological improvement prior to groin puncture suggestive of resolution of&#xD;
             stroke&#xD;
&#xD;
          -  Seizures at stroke onset if it makes the diagnosis of stroke doubtful and precludes&#xD;
             obtaining an accurate baseline NIHSS assessment.&#xD;
&#xD;
               -  Note: Subjects with a questionable seizure at onset of stroke should not be&#xD;
                  excluded if DSA confirms the presence of intracranial ICA and/or M1 occlusion,&#xD;
                  and accurate NIHSS can be obtained.&#xD;
&#xD;
          -  Pre-existing medical neurological or psychiatric disease that would confound the&#xD;
             neurological or functional evaluations, e.g. dementia with prescribed&#xD;
             anti-cholinesterase inhibitor (e.g. Aricept).&#xD;
&#xD;
          -  Cardiopulmonary resuscitation, significant cardiac arrhythmia, evidence of ongoing&#xD;
             myocardial infarction, concern for pre-treatment pulmonary aspiration.&#xD;
&#xD;
          -  Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.&#xD;
&#xD;
          -  Cerebral vasculitis.&#xD;
&#xD;
          -  History of severe allergy to contrast medium.&#xD;
&#xD;
          -  Known allergy to stent retriever materials (nitinol, stainless steel);&#xD;
&#xD;
          -  Suspicion of aortic dissection, septic embolus, or bacterial endocarditis.&#xD;
&#xD;
          -  Active infection.&#xD;
&#xD;
          -  Baseline CT or MRI showing mass effect or intracranial tumor (except small meningioma&#xD;
             [≤ 3 cm]).&#xD;
&#xD;
          -  CT or MRI evidence of recent/fresh hemorrhage on presentation.&#xD;
&#xD;
          -  CTA, MRA, or DSA evidence of flow limiting carotid dissection, high-grade stenosis, or&#xD;
             complete cervical carotid occlusion requiring stenting at the time of the index&#xD;
             procedure (i.e., mechanical thrombectomy).&#xD;
&#xD;
          -  Evidence of dissection in the intracranial cerebral arteries;&#xD;
&#xD;
          -  Uncontrolled hypertension on presentation (defined as SBP &gt; 220 mmHg and / or DBP &gt;&#xD;
             120 mmHg). For subjects placed on intravenous BP medication, uncontrolled hypertension&#xD;
             is defined as SBP &gt; 185 mmHg and / or DBP &gt; 110 mmHg.&#xD;
&#xD;
          -  Baseline hemoglobin of &lt; 7 mmol/L.&#xD;
&#xD;
          -  Baseline platelet count &lt; 50,000/uL.&#xD;
&#xD;
          -  Renal failure as defined by a serum creatinine &gt;3.0 mg/dL (264 mmol/L).&#xD;
&#xD;
               -  Note: subjects on renal dialysis may be treated regardless of serum creatinine&#xD;
                  levels.&#xD;
&#xD;
          -  Known hemorrhagic diathesis, coagulation factor deficiency, or on anticoagulant&#xD;
             therapy with INR &gt; 3.0 or PTT &gt; 3 times normal. Subjects on factor Xa inhibitor for&#xD;
             24-48 h ago must have a normal PTT.&#xD;
&#xD;
          -  Baseline blood glucose of &lt; 50 mg/dL (2.78 mmol) or &gt; 400 mg/dL (22.20 mmol). Note:&#xD;
             The ''correction'' of baseline glucose or coagulation laboratory values to meet&#xD;
             inclusion criteria will not be allowed.&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Known current or recent use of illicit drugs or alcohol abuse.&#xD;
&#xD;
          -  Use of an investigational drug or device within past 3 months;&#xD;
&#xD;
          -  Life expectancy less than 6 months.&#xD;
&#xD;
          -  Any other condition that, in the opinion of the investigator, precludes an&#xD;
             endovascular procedure or poses a significant hazard to the subject if an endovascular&#xD;
             procedure was performed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raul Gomes Nogueira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

